Home Healthcare Market Could Hit $666.3 billion by 2030

According to research from Grand View Research, Inc, the home healthcare market could be worth $666.3 billion by 2030. This is based on an estimated CAGR of 7.96%.

This industry includes home health care services (like nursing care and nutritional support) and home health care supplies (like wheelchairs and sleep monitors).

Why is the home healthcare market booming?

The aging population is increasing as the result of more people living longer. Currently, about 1 in 10 people in the world are over 65. By 2050, about 1 in 6 people will likely be aged over 65.

More seniors means more people with chronic degenerative health conditions. These health conditions typically require medication, equipment or physical support from carers in order to treat.

Dementia uses up a lot of home healthcare resources and cases are likely to increase in years to come. Currently, there are about 50 million dementia patients in the world. This is estimated to increase to 82 million by 2030.

Care homes have been getting less accessible over the years due to increasing fees. As a result, more people are relying on home health care – a trend that will likely continue unless seniors or care homes are able to attract more public funding.

It’s worth noting that a growth in young people with disabilities is also contributing to increased demand for home healthcare. However, senior citizens still make up the vast majority of home patients and are likely to be the biggest focus in years to come.

What type of home healthcare is in demand?

Home health care services make up much of the market’s value. Skilled at-home nurses are believed to become increasingly in-demand – this includes carrying out medical services like wound dressing, tube feedings and rehabilitation. This is necessary to take the demand off of hospitals and nursing homes.

Home therapeutic equipment is likely to experience the biggest CAGR in years to come. This is largely due to an increase in chronic health conditions like diabetes, COPD and kidney disease. Some of the equipment that is likely to become more in demand includes blood sugar monitors, insulin pumps, supplemental oxygen, CPAP machines and home dialysis equipment.

What are some of the future trends we will see in home healthcare?

Home automation or ‘internet of things’ (IoT) technology is certain to make massive advancements in years to come. Already, telemonitoring machines are gaining popularity, allowing constant remote monitoring of patients’ vital signs at home. Smart pill dispensers can also help to organize pills and dispense them at certain times of the day – often triggering alarms, which may also send an alert to a patient’s phone.

AI and robotics will enable more treatments to be automatically carried out at home. However, we are unlikely to see such technology being commonly introduced before 2030. Right now a lot of this tech is still very expensive to implement and many seniors still want to be treated by physical carers. Increased recruitment of skilled nurses will be needed in order to meet this demand.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”